Hivotex (Ambroxol Hydrochloride)

Hivotex is indicated for the symptomatic relief of respiratory conditions characterized by thick, tenacious mucus. It is commonly employed in both acute and chronic airway disorders where enhanced clearance is desired. The medication is taken orally and works systemically to improve mucociliary function.

• Cough associated with thick, productive sputum.
• Acute bronchitis with mucus hypersecretion.
• Chronic bronchitis to aid mucus expectoration.
• Exacerbations of chronic obstructive pulmonary disease (COPD).
• Post‑viral respiratory infections where mucus clearance is impaired.
• Respiratory tract infections with productive cough.
• Mucus retention after inhalation therapy in asthma patients.

• Ambroxol hydrochloride acts as a mucolytic by stimulating the synthesis and release of pulmonary surfactant and by disrupting the disulfide bonds within mucus glycoproteins. This reduces mucus viscosity and elasticity, facilitating ciliary movement and enhancing mucociliary clearance. The drug also has a mild local anesthetic effect on airway sensory nerves, which may contribute to cough suppression. Overall, the pharmacodynamic profile supports improved airway patency during respiratory infections.

Adverse reactions to Hivotex are generally mild and transient, affecting the gastrointestinal tract or skin, but occasional serious events have been reported that may require medical attention.

Common

• Nausea or upset stomach, often occurring shortly after ingestion.
• Diarrhea or loose stools, typically mild and self‑limiting.
• Taste disturbances, including a metallic or bitter sensation in the mouth.
• Mild skin rash or itching, usually localized.
• Headache, transient and not dose‑related.
• Dizziness, generally mild and resolves with continued use.

Serious

• Severe allergic reactions such as angioedema, which may involve swelling of the face, lips, or throat.
• Hepatic enzyme elevation, detected on routine laboratory testing.
• Acute bronchospasm (rare), presenting as sudden wheezing and shortness of breath.
• Persistent vomiting leading to dehydration, especially in vulnerable populations.
• Blood dyscrasias such as neutropenia (very rare), requiring hematologic monitoring.

When using Hivotex, certain precautions should be observed to minimize risk and ensure appropriate use.

• Assess for known hypersensitivity to ambroxol or any excipients before initiating therapy.
• Use with caution in patients with hepatic impairment; monitor liver function if therapy is prolonged.
• Consider dose adjustment or close observation in renal insufficiency, as metabolites are renally excreted.
• Avoid use in children under the age recommended by local labeling without medical advice.
• Pregnant or breastfeeding women should consult a healthcare professional before use.
• Patients with a history of asthma should be monitored for bronchospasm.
• Concomitant use of other mucolytics may increase the risk of gastrointestinal irritation.

Hivotex may interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Avoid

• Concurrent use with potent anticholinergic agents that may reduce mucociliary clearance.
• Combination with other strong mucolytics or expectorants, which can cause excessive mucus thinning.

Use with caution

• Co‑administration with drugs metabolized by hepatic enzymes CYP2D6, as ambroxol can inhibit this pathway.
• Use together with anticoagulants, as rare reports suggest increased bleeding tendency.
• Concomitant use with bronchodilators may enhance cough suppression, requiring monitoring.
• Patients on antihistamines should be observed for additive sedation, though uncommon.